Research Papers

25 of 40 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development.
Haynes BF; Wiehe K; Alam SM; Weissman D; Saunders KO.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Discovery medicine - the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine.
Martin TM; Robinson ST; Huang Y.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
'Immunization during ART and ATI for HIV-1 vaccine discovery/development'.
Stamatatos L.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Accelerating HIV vaccine development through meaningful engagement of local scientists and communities.
Chinyenze K; Nduati E; Muturi-Kioi V.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment…
Herbert NG; Goulder PJR.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Defining multimorbidity in people with HIV - what matters most?
Sukumaran L; Sabin CA.
Curr Opin HIV AIDS (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Whole person HIV services: a social science approach.
Van Heerden A; Humphries H; Geng E.
Curr Opin HIV AIDS (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117.
Zacharopoulou P; Ansari MA; Frater J.
Curr Opin HIV AIDS (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel preventive and cure strategi…
Calvet-Mirabent M; Martín-Gayo E.
Curr Opin HIV AIDS (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of …
Philbin MM; Perez-Brumer A.
Curr Opin HIV AIDS (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Exosomes in HIV infection.
Chen J; Li C; Li R; Chen H; Chen D; Li W.
Curr Opin HIV AIDS (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2.
McCormick KD; Mellors JW; Jacobs JL.
Curr Opin HIV AIDS (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
HIV care during the coronavirus disease-2019 pandemic in Shenzhen, China.
Wang H.
Curr Opin HIV AIDS (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia: what will it take?
Deryabina AP; El-Sadr WM.
Curr Opin HIV AIDS (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
The HIV epidemic in Latin America: accomplishments and challenges on treatment and prevention.
Luz PM; Veloso VG; Grinsztejn B.
Curr Opin HIV AIDS (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms.
Brouwer PJM; Sanders RW.
Curr Opin HIV AIDS (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis r…
Walker NF; Stek C; Wasserman S; Wilkinson RJ; Meintjes G.
Curr Opin HIV AIDS (Unknown)
Published: 2018
2/6 Transparent
Funding Declared
Modeling HIV persistence and cure studies.
Hill AL.
Curr Opin HIV AIDS (Unknown)
Published: 2018
2/6 Transparent
Funding Declared
Neutralization tiers of HIV-1.
Montefiori DC; Roederer M; Morris L; Seaman MS.
Curr Opin HIV AIDS (Unknown)
Published: 2018
2/6 Transparent
Funding Declared
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.
Venter WDF; Clayden P; Serenata C; OPTIMIZE Consortium.
Curr Opin HIV AIDS (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
Medina-Ramírez M; Sanders RW; Sattentau QJ.
Curr Opin HIV AIDS (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
Lessons learned from human HIV vaccine trials.
Pollara J; Easterhoff D; Fouda GG.
Curr Opin HIV AIDS (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
Lessons from acute HIV infection.
Robb ML; Ananworanich J.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Persistent HIV-1 replication during antiretroviral therapy.
Martinez-Picado J; Deeks SG.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared
Bone health and HIV in resource-limited settings: a scoping review.
Matovu FK; Wattanachanya L; Beksinska M; Pettifor JM; Ruxrungtham K.
Curr Opin HIV AIDS (Unknown)
Published: 2016
2/6 Transparent
Funding Declared